Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: One-year findings from the IVAN randomized trial

Tariq Aslam; Usha Chakravarthy; Simon P. Harding; Chris A. Rogers; Susan M. Downes; Andrew J. Lotery; Sarah Wordsworth; Barnaby C. Reeves; Paul Bishop

doi:10.1016/j.ophtha.2012.04.015

Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: One-year findings from the IVAN randomized trial

Tariq Aslam, Usha Chakravarthy, Simon P. Harding, Chris A. Rogers, Susan M. Downes, Andrew J. Lotery, Sarah Wordsworth, Barnaby C. Reeves, Paul Bishop

Research output: Contribution to journal › Article › peer-review

Abstract

Purpose: To compare the efficacy and safety of ranibizumab and bevacizumab intravitreal injections to treat neovascular age-related macular degeneration (nAMD). Design: Multicenter, noninferiority factorial trial with equal allocation to groups. The noninferiority limit was 3.5 letters. This trial is registered (ISRCTN92166560). Participants: People >50 years of age with untreated nAMD in the study eye who read

Original language	English
Pages (from-to)	1399-1411
Number of pages	12
Journal	Ophthalmology
Volume	119
Issue number	7
DOIs	https://doi.org/10.1016/j.ophtha.2012.04.015
Publication status	Published - Jul 2012

Access to Document

10.1016/j.ophtha.2012.04.015

Cite this

@article{210b1f107d994d25acf5cf7f2ec3137c,

title = "Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: One-year findings from the IVAN randomized trial",

abstract = "Purpose: To compare the efficacy and safety of ranibizumab and bevacizumab intravitreal injections to treat neovascular age-related macular degeneration (nAMD). Design: Multicenter, noninferiority factorial trial with equal allocation to groups. The noninferiority limit was 3.5 letters. This trial is registered (ISRCTN92166560). Participants: People >50 years of age with untreated nAMD in the study eye who read",

author = "Tariq Aslam and Usha Chakravarthy and Harding, {Simon P.} and Rogers, {Chris A.} and Downes, {Susan M.} and Lotery, {Andrew J.} and Sarah Wordsworth and Reeves, {Barnaby C.} and Paul Bishop",

note = ", Department of Health, United Kingdom",

year = "2012",

month = jul,

doi = "10.1016/j.ophtha.2012.04.015",

language = "English",

volume = "119",

pages = "1399--1411",

journal = "Ophthalmology",

issn = "1549-4713",

publisher = "Elsevier BV",

number = "7",

}

TY - JOUR

T1 - Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: One-year findings from the IVAN randomized trial

AU - Aslam, Tariq

AU - Chakravarthy, Usha

AU - Harding, Simon P.

AU - Rogers, Chris A.

AU - Downes, Susan M.

AU - Lotery, Andrew J.

AU - Wordsworth, Sarah

AU - Reeves, Barnaby C.

AU - Bishop, Paul

N1 - , Department of Health, United Kingdom

PY - 2012/7

Y1 - 2012/7

N2 - Purpose: To compare the efficacy and safety of ranibizumab and bevacizumab intravitreal injections to treat neovascular age-related macular degeneration (nAMD). Design: Multicenter, noninferiority factorial trial with equal allocation to groups. The noninferiority limit was 3.5 letters. This trial is registered (ISRCTN92166560). Participants: People >50 years of age with untreated nAMD in the study eye who read

AB - Purpose: To compare the efficacy and safety of ranibizumab and bevacizumab intravitreal injections to treat neovascular age-related macular degeneration (nAMD). Design: Multicenter, noninferiority factorial trial with equal allocation to groups. The noninferiority limit was 3.5 letters. This trial is registered (ISRCTN92166560). Participants: People >50 years of age with untreated nAMD in the study eye who read

U2 - 10.1016/j.ophtha.2012.04.015

DO - 10.1016/j.ophtha.2012.04.015

M3 - Article

C2 - 22578446

SN - 1549-4713

VL - 119

SP - 1399

EP - 1411

JO - Ophthalmology

JF - Ophthalmology

IS - 7

ER -

Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: One-year findings from the IVAN randomized trial

Abstract

Access to Document

Fingerprint

Cite this